Watson Launches Generic Xopenex
Xopenex Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children >6 years of age with reversible obstructive airway disease. Levalbuterol is a β2-agonist that relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles.
Levalbuterol HCl Inhalation Solution will be available in 0.31mg/3mL, 0.63mg/3mL, and 1.25mg/3mL dosage strengths. Watson began shipping the product today.
For more information call (800) 272-5525 or visit www.watson.com.